Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + camrelizumab + gemcitabine vs gemcitabine + oxaliplatin for first-line treatment of advanced bile duct cancer (Phase II)
ChiCTR2100044048Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Mar 2021
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in cholangiocarcinoma (CCA) comparing Anlotinib + camrelizumab + gemcitabine with Gemcitabine + oxaliplatin (2 arms). Primary endpoint: Objective response rate. Started Mar 2021; status: recruiting.
02
Drugs
anlotinibcamrelizumabgemcitabineoxaliplatin
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on ChiCTR2100044048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100044048.